S&P 500   3,316.41 (+1.08%)
DOW   27,300.96 (+0.56%)
QQQ   272.96 (+2.04%)
AAPL   112.26 (+1.98%)
MSFT   207.63 (+2.51%)
FB   254.87 (+2.71%)
GOOGL   1,461.42 (+2.19%)
AMZN   3,127.45 (+5.64%)
NVDA   505.56 (+0.97%)
TSLA   427.83 (-4.80%)
BABA   275.25 (+0.52%)
CGC   16.02 (+1.78%)
GE   6.24 (-1.73%)
MU   49.67 (+1.06%)
AMD   77.47 (-0.60%)
T   28.53 (-0.35%)
F   6.81 (-0.87%)
ACB   7.40 (+17.09%)
GILD   63.49 (-1.12%)
NFLX   491.57 (+0.87%)
DIS   127.47 (+1.64%)
BAC   23.87 (-2.45%)
BA   156.77 (+0.27%)
S&P 500   3,316.41 (+1.08%)
DOW   27,300.96 (+0.56%)
QQQ   272.96 (+2.04%)
AAPL   112.26 (+1.98%)
MSFT   207.63 (+2.51%)
FB   254.87 (+2.71%)
GOOGL   1,461.42 (+2.19%)
AMZN   3,127.45 (+5.64%)
NVDA   505.56 (+0.97%)
TSLA   427.83 (-4.80%)
BABA   275.25 (+0.52%)
CGC   16.02 (+1.78%)
GE   6.24 (-1.73%)
MU   49.67 (+1.06%)
AMD   77.47 (-0.60%)
T   28.53 (-0.35%)
F   6.81 (-0.87%)
ACB   7.40 (+17.09%)
GILD   63.49 (-1.12%)
NFLX   491.57 (+0.87%)
DIS   127.47 (+1.64%)
BAC   23.87 (-2.45%)
BA   156.77 (+0.27%)
S&P 500   3,316.41 (+1.08%)
DOW   27,300.96 (+0.56%)
QQQ   272.96 (+2.04%)
AAPL   112.26 (+1.98%)
MSFT   207.63 (+2.51%)
FB   254.87 (+2.71%)
GOOGL   1,461.42 (+2.19%)
AMZN   3,127.45 (+5.64%)
NVDA   505.56 (+0.97%)
TSLA   427.83 (-4.80%)
BABA   275.25 (+0.52%)
CGC   16.02 (+1.78%)
GE   6.24 (-1.73%)
MU   49.67 (+1.06%)
AMD   77.47 (-0.60%)
T   28.53 (-0.35%)
F   6.81 (-0.87%)
ACB   7.40 (+17.09%)
GILD   63.49 (-1.12%)
NFLX   491.57 (+0.87%)
DIS   127.47 (+1.64%)
BAC   23.87 (-2.45%)
BA   156.77 (+0.27%)
S&P 500   3,316.41 (+1.08%)
DOW   27,300.96 (+0.56%)
QQQ   272.96 (+2.04%)
AAPL   112.26 (+1.98%)
MSFT   207.63 (+2.51%)
FB   254.87 (+2.71%)
GOOGL   1,461.42 (+2.19%)
AMZN   3,127.45 (+5.64%)
NVDA   505.56 (+0.97%)
TSLA   427.83 (-4.80%)
BABA   275.25 (+0.52%)
CGC   16.02 (+1.78%)
GE   6.24 (-1.73%)
MU   49.67 (+1.06%)
AMD   77.47 (-0.60%)
T   28.53 (-0.35%)
F   6.81 (-0.87%)
ACB   7.40 (+17.09%)
GILD   63.49 (-1.12%)
NFLX   491.57 (+0.87%)
DIS   127.47 (+1.64%)
BAC   23.87 (-2.45%)
BA   156.77 (+0.27%)
Log in
NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$5.05
+0.06 (+1.20 %)
(As of 09/22/2020 03:43 PM ET)
Add
Compare
Today's Range
$4.85
Now: $5.05
$5.05
50-Day Range
$4.81
MA: $5.04
$5.68
52-Week Range
$3.35
Now: $5.05
$14.44
Volume10,300 shs
Average Volume323,519 shs
Market Capitalization$407.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Rubius Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Employees142
Market Cap$407.87 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$5.05
+0.06 (+1.20 %)
(As of 09/22/2020 03:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

How has Rubius Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RUBY stock has decreased by 22.9% and is now trading at $5.05.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rubius Therapeutics
.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.03.
View Rubius Therapeutics' earnings history
.

What price target have analysts set for RUBY?

5 analysts have issued 1-year target prices for Rubius Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' stock price to reach $11.20 in the next year. This suggests a possible upside of 121.8% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (12.93%), Artal Group S.A. (4.77%), Federated Hermes Inc. (0.75%), Jacobs Levy Equity Management Inc. (0.46%), Charles Schwab Investment Management Inc. (0.29%) and Bank of New York Mellon Corp (0.19%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics
.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, and Artal Group S.A.. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, and Robert Langer.
View insider buying and selling activity for Rubius Therapeutics
.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Jacobs Levy Equity Management Inc., PDT Partners LLC, Virtus ETF Advisers LLC, Trexquant Investment LP, Goldman Sachs Group Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $5.05.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $407.87 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.